About TARGET PharmaSolutions
TARGET PharmaSolutions is a company based in Chapel Hill (United States) founded in 2015 by Meg Boothpowell and Michael Fried was acquired by Norwest Venture Partners in June 2016. TARGET PharmaSolutions has raised $2 million across 1 funding round from investors including Novartis, Boehringer Ingelheim and Allergan.
- Headquarter Chapel Hill, United States
- Founders Meg Boothpowell, Michael Fried
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$2 M (USD)
in 1 rounds
-
Latest Funding Round
$2 M (USD), Series A
Jan 13, 2016
-
Investors
Novartis
& 6 more
-
Employee Count
Not available
-
Acquired by
Norwest Venture Partners
(Jun 01, 2016)
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
People of TARGET PharmaSolutions
Unlock access to complete
Unlock access to complete
Funding Insights of TARGET PharmaSolutions
TARGET PharmaSolutions has successfully raised a total of $2M through 1 strategic funding round. The most recent funding activity was a Series A round of $2 million completed in January 2016. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in TARGET PharmaSolutions
TARGET PharmaSolutions has secured backing from 7 investors, including venture fund and institutional investors. Prominent investors backing the company include Novartis, Boehringer Ingelheim and Allergan.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
Early-stage ventures in the Southeast are supported by VentureSouth.
|
Locked | Locked | Locked | |
|
Venture capital and growth equity firm providing investments and resources to entrepreneurs in various sectors.
|
Locked | Locked | Locked |
Investor details for TARGET PharmaSolutions
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by TARGET PharmaSolutions
Investment portfolio details for TARGET PharmaSolutions
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - TARGET PharmaSolutions
Detailed financials for TARGET PharmaSolutions
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Target Pharmasolutions Comparisons
Peer comparison for TARGET PharmaSolutions
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of TARGET PharmaSolutions
Detailed competitors of TARGET PharmaSolutions
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Target Pharmasolutions
Complete news archive for TARGET PharmaSolutions
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about TARGET PharmaSolutions
TARGET PharmaSolutions was founded in 2015 and raised its 1st funding round 1 year after it was founded.
TARGET PharmaSolutions is headquartered in Chapel Hill, United States. It is registered at Chapel Hill, North Carolina, United States.
Michael Mckelvey is the current CEO of TARGET PharmaSolutions.
TARGET PharmaSolutions is a funded company, having raised a total of $2M across 1 funding round to date.
TARGET PharmaSolutions was established in 2015 in Chapel Hill, United States. Clinical data management and consulting services are delivered to support pharmaceutical operations. Focus is placed on data handling, analysis, and advisory expertise within the healthcare sector. The company is led by co-founders Meg Boothpowell and Michael Fried, alongside CEO Michael Mckelvey. Activities are centered in the U.S., addressing needs in clinical research and compliance.
TARGET PharmaSolutions has 7 investors. Key investors include Novartis, Boehringer Ingelheim, Allergan, Norwest Venture Partners, and Rex Health Ventures.